Clinical trials: CART Therapy
Solid Tumor
A Clinical Study on the Safety and Efficacy of Chimeric Antigen Receptor T-cell (CART) in the Treatment of Solid Tumors
This is a single-arm, investigator-initiated exploratory study.The study is designed to evaluate the safety and the tolerability of HER2-E-CART cells for the treatment of patients with HER2-positive, refractory advanced solid…
- Trial name
- NCT05745454
- Testing
- HER2-E-CART cells
- Volunteers
- 12 people
- Sponsor
- su haichuan
Advanced EGFR-positive Solid Tumors
Treatment of Chemotherapy Refractory EGFR(Epidermal Growth Factor Receptor) Positive Advanced Solid Tumors (CART-EGFR)
RATIONALE: Placing a tumor antigen chimeric receptor that has been created in the laboratory into patient autologous T cells may make the body build immune response to kill cancer cells.
- Trial name
- CART-EGFR (NCT01869166)
- Testing
- CART-EGFR
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Chinese PLA General Hospital
Multiple Myeloma
Efficacy and Safety Evaluation of PD1-BCMA-CART
This trial aims to evaluate the safety and efficacy of PD1-BCMA-CART in treating patients with relapsed or refractory multiple myeloma.
- Trial name
- NCT05308875
- Testing
- PD1-BCMA-CART
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Bioray Laboratories
Multiple Myeloma
A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy
The researchers are doing this study to find out whether talquetamab is an effective treatment after BCMA CAR Tcell therapy for people with relapsed or refractory multiple myeloma.
- Trial name
- NCT06066346
- Testing
- Talquetamab
- Where
- 7 sites in United States
- Volunteers
- 17 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Multiple Myeloma
Study of PD-1Ab21-BCMA CAR-T Therapy for Consolidation of Multiple Myelomawith Renal Dysfunction
The purpose of this study is to determine the efficacy and safety of targeted BCMA CART cells secreting PD1 and interleukin 21 fusion protein immunotherapy for first-line consolidation therapy of multiple myeloma with renal…
- Trial name
- NCT07489534
- Testing
- PD-1Ab21-BCMA CAR-T cell immunotherapy
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Daihong Liu
Relapsed/Refractory Multiple Myeloma (MM)
Clinical Study of BCMA-Targeted CAR T-Cell Injection in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma
A Phase 1b clinical trial to evaluate the safety and efficacy of BCMA-targeted CAR T-cell therapy in Thai patients with relapsed or refractory multiple myeloma.
- Trial name
- CART-BCMA (NCT07458659)
- Testing
- Chimeric Antigen Receptor T Cells (CAR-T)
- Where
- Thailand
- Volunteers
- 3 people
- Sponsor
- Chulalongkorn University
Malignant Mesothelioma, Pancreatic Cancer
Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso
RATIONALE: Placing a tumor antigen chimeric receptor that has been created in the laboratory into patient autologous or donor-derived T cells may make the body build immune response to kill cancer cells.
- Conditions
- Malignant Mesothelioma, Pancreatic Cancer, Ovarian Tumor, Triple Negative Breast Cancer
- Trial name
- NCT02580747
- Testing
- anti-meso-CAR vector transduced T cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Chinese PLA General Hospital
Multiple Myeloma
A Study of VRd-based Regimen Combined With CART-ASCT-CART2 Treatment in NDMM Patients With P53 Abnormalities
This is a single-arm, open-label study to evaluate the efficacy and safety of VRD(Bortezomib, Lenalidomide and Dexamethasone)-based regimen combined with CART-ASCT-CART2 in patients with newly diagnosed multiple myeloma with p53…
- Trial name
- NCT05850286
- Testing
- anti-BCMA CAR-T, VRD-based Regimen
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
ALL, Childhood B-Cell
Study of alloCART-19 Cell Therapy in Pediatric Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
The purpose of this study is to evaluate the safety and tolerability of CD19-Directed Allogeneic Chimeric Antigen Receptor T- cell (alloCART-19)therapy in pediatric patients with relapsed/refractory acute lymphoblastic…
- Trial name
- NCT04173988
- Testing
- alloCART-19, Cyclophosphamide, Fludarabine
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Children's Hospital of Fudan University
Neoplasm, Stomach, Metastases, Neoplasm
Intraperitoneal Infusion of EpCAM CAR-T Cell in Advanced Gastric Cancer With Peritoneal Metastasis (WCH-GC-CART)
To investigate the safety and efficacy of intraperitoneal infusion of EpCAM CAR-T cell in advanced gastric cancer with peritoneal metastasis by a prospective nonrandomized controlled trial.
- Conditions
- Neoplasm, Stomach, Metastases, Neoplasm, Neoplasm Seeding
- Trial name
- NCT03563326
- Testing
- CAR-T cells targeting EpCAM, Chemotherapy
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Jian-Kun Hu
Relapsed Refractory Multiple Myeloma
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
This is a randomised, multicentre, controlled, open-label, Phase III global study comparing the efficacy and safety of AZD0120 versus standard regimens (DKd [daratumumab, carfilzomib, and dexamethasone], DPd [daratumumab…
- Trial name
- DURGA-4 (NCT07391657)
- Testing
- AZD0120, Daratumumab, Carfilzomib
- Where
- 143 sites in United States, Australia and 13 more
- Volunteers
- 508 people
- Sponsor
- AstraZeneca
HIV-1 Infection
MARCH Central Nervous System Substudy
This substudy is a prospective, observational, open-label, randomised study within the MARCH study. The purpose of this substudy is to investigate the changes in cerebral function parameters at 5 timepoints over 96 weeks of the…
- Trial name
- NCT01637233
- Testing
- Arm 1 TNucleotide Analogue Reverse Transcriptase Inhibitors and Boosted Protease Inhibitors, Arm 2 Maraviroc and Protease Inhibitors, Arm 3 Maraviroc and Nucleotide Analogue Reverse Transcriptase Inhibitors
- Where
- 6 sites in Argentina, Thailand and 1 more
- Volunteers
- 28 people
- Sponsor
- Kirby Institute
B-Cell Non-Hodgkin Lymphoma-Recurrent, Diffuse Large B-Cell Lymphoma-Recurrent
CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma
This phase I trial tests the safety, side effects and best dose of CC-99282 with rituximab for the treatment of patients who have received chimeric antigen receptor (CAR) T cell therapy for non-Hodgkins lymphoma and in whom have…
- Conditions
- B-Cell Non-Hodgkin Lymphoma-Recurrent, Diffuse Large B-Cell Lymphoma-Recurrent, Follicular Lymphoma-Recurrent, High Grade B-Cell Lymphoma-Recurrent
- Trial name
- NCT06209619
- Testing
- Biopsy, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Nathan Denlinger
HIV-1-infection
Immune Activation Markers in HIV-infected Patients Switching to Long Acting Dual Therapy
The purpose of the study is to measure the impact on immune activation and inflammatory markers of switching from a triple combination antiretroviral therapy (cART) to a long acting dual therapy in HIV-infected patients
- Trial name
- LONGADAPT (NCT05433987)
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Centre Hospitalier de Cannes Simone Veil
Non-hodgkin Lymphoma, Refractory Lymphoma
GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHL
To evaluate the safety and tolerability of GB5005 in patients with CD19-positive relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL).
- Conditions
- Non-hodgkin Lymphoma, Refractory Lymphoma, Chimeric Antigen Receptor T-cell
- Trial name
- NCT06875063
- Testing
- GB5005 CART
- Where
- China
- Volunteers
- 45 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Relapsed/Refractory Multiple Myeloma(MM)
CAR-T Cells Therapy in Relapsed/Refractory Multiple Myeloma
Multiple myeloma（MM） is one of the most common malignant diseases in the blood system.There is still no cure for the disease which only control the development of the disease in various ways.Chimeric Antigen Receptor-transduced T…
- Trial name
- MM (NCT03473496)
- Testing
- CART therapy in Relapsed/Refractory multiple myeloma
- Where
- China
- Volunteers
- 2 people
- Sponsor
- Zhujiang Hospital
Intrahepatic Cholangiocarcinoma
Safety and Efficacy Evaluation of MUC-1 CART in the Treatment of Intrahepatic Cholangiocarcinoma
Intrahepatic cholangiocarcinoma (ICC) is one of the most common liver malignancies. Surgical treatment is the first choice. However, for patients without surgical indications, the benefits of conventional chemoradiotherapy are…
- Trial name
- NCT03633773
- Testing
- MUC-1 CART cell immunotherapy
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
HIV Infections
Safety and Immune Response of BMS-936559 in HIV-Infected People Taking Combination Antiretroviral Therapy
People infected with HIV may have low levels of the virus in their body, even if they are taking HIV medications. This study will evaluate the safety, pharmacokinetics (PK) (which is how the body interacts with drugs), and immune…
- Trial name
- NCT02028403
- Testing
- BMS-936559
- Where
- 5 sites in United States
- Volunteers
- 8 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Vaccine Immunity in CAR-T Cell Therapy Recipients
Restoration of Immunity to Vaccine Preventable Diseases After CART-T Cell Therapy
The goal of this observational study is to learn about vaccine immunity in patients with B-cell malignancies treated by chimeric antigen receptor T-cell therapies (CAR-T).
- Trial name
- IMCAR (NCT06333275)
- Testing
- Vaccines against: Diphtheria, tetanus, pertussis, polio, haemophilus influenza type b, varicella and measles
- Where
- Switzerland
- Volunteers
- 80 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Acute Myeloid Leukemia
Anti-CLL1 CAR T-cell Therapy in CLL1 Positive Relapsed/Refractory Acute Myeloid Leukemia (AML)
This is a single center, open-label phase 1/2 study to evaluate the safety and efficacy of anti-CLL1 chimeric antigen receptor engineered T cell immunotherapy (CART) in the treatment of CLL1 positive relapsed or refractory acute…
- Trial name
- NCT04884984
- Testing
- anti-CLL1 CART
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The First Affiliated Hospital of Soochow University